High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies

Peter Dreger, Paolo Ghia, Johannes Schetelig, Michel van Gelder, Eva Kimby, Mauricette Michallet, Carol Moreno, Tadeusz Robak, Stephan Stilgenbauer, Emili Montserrat, ERIC; European Soc Blood Marrow

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)892-902
Number of pages11
JournalBlood
Volume132
Issue number9
DOIs
Publication statusPublished - 30 Aug 2018

Keywords

  • VERSUS-HOST-DISEASE
  • GCLLSG CLL3X TRIAL
  • MARROW TRANSPLANTATION
  • OPEN-LABEL
  • FOLLOW-UP
  • ALLOGENEIC TRANSPLANTATION
  • CLONAL EVOLUTION
  • EUROPEAN-SOCIETY
  • RICHTER TRANSFORMATION
  • RETROSPECTIVE ANALYSIS

Cite this

Dreger, P., Ghia, P., Schetelig, J., van Gelder, M., Kimby, E., Michallet, M., Moreno, C., Robak, T., Stilgenbauer, S., Montserrat, E., & ERIC; European Soc Blood Marrow (2018). High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies. Blood, 132(9), 892-902. https://doi.org/10.1182/blood-2018-01-826008